105 related articles for article (PubMed ID: 23589639)
1. Mitoxantrone-related acute leukemia in MS: an open or closed book?
Chan A; Lo-Coco F
Neurology; 2013 Apr; 80(16):1529-33. PubMed ID: 23589639
[TBL] [Abstract][Full Text] [Related]
2. Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
Ellis R; Brown S; Boggild M
Mult Scler; 2015 Apr; 21(5):642-5. PubMed ID: 25013152
[TBL] [Abstract][Full Text] [Related]
3. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
Ellis R; Boggild M
Mult Scler; 2009 Apr; 15(4):505-8. PubMed ID: 19251838
[TBL] [Abstract][Full Text] [Related]
4. [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].
Meyer C; Ansorge N; Siglienti I; Salmen S; Stroet A; Nückel H; Dührsen U; Ritter PR; Schmidt WE; Gold R; Chan A
Nervenarzt; 2010 Dec; 81(12):1483-9. PubMed ID: 21079910
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
Colovic N; Suvajdzic N; Kraguljac Kurtovic N; Djordjevic V; Dencic Fekete M; Drulovic J; Vidovic A; Tomin D
Biomed Pharmacother; 2012 Apr; 66(3):173-4. PubMed ID: 22440894
[TBL] [Abstract][Full Text] [Related]
6. Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.
Hasan SK; Buttari F; Ottone T; Voso MT; Hohaus S; Marasco E; Mantovani V; Garagnani P; Sanz MA; Cicconi L; Bernardi G; Centonze D; Lo-Coco F
Neurology; 2011 Mar; 76(12):1059-65. PubMed ID: 21346221
[TBL] [Abstract][Full Text] [Related]
7. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
[TBL] [Abstract][Full Text] [Related]
8. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.
Brassat D; Recher C; Waubant E; Le Page E; Rigal-Huguet F; Laurent G; Edan G; Clanet M
Neurology; 2002 Sep; 59(6):954-5. PubMed ID: 12297591
[TBL] [Abstract][Full Text] [Related]
9. Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation.
Ottone T; Hasan SK; Montefusco E; Curzi P; Mays AN; Chessa L; Ferrari A; Conte E; Noguera NI; Lavorgna S; Ammatuna E; Divona M; Bovetti K; Amadori S; Grimwade D; Lo-Coco F
Genes Chromosomes Cancer; 2009 Mar; 48(3):213-21. PubMed ID: 19023877
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients.
Voltz R; Starck M; Zingler V; Strupp M; Kolb HJ
Mult Scler; 2004 Aug; 10(4):472-4. PubMed ID: 15327049
[TBL] [Abstract][Full Text] [Related]
11. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
Ramkumar B; Chadha MK; Barcos M; Sait SN; Heyman MR; Baer MR
Cancer Genet Cytogenet; 2008 Apr; 182(2):126-9. PubMed ID: 18406875
[TBL] [Abstract][Full Text] [Related]
12. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
13. [Mitoxantrone].
Pericot I; Montalban X
Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis.
Kornek B; Bernert G; Rostasy K; Mlczoch E; Feucht M; Prayer D; Vass K; Seidl R
Neuropediatrics; 2011 Feb; 42(1):7-12. PubMed ID: 21557144
[TBL] [Abstract][Full Text] [Related]
15. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Marriott JJ; Miyasaki JM; Gronseth G; O'Connor PW;
Neurology; 2010 May; 74(18):1463-70. PubMed ID: 20439849
[TBL] [Abstract][Full Text] [Related]
16. Therapy-related acute nonlymphoblastic leukemia following mitoxantrone therapy in a patient with multiple sclerosis.
Sumrall A; Dreiling B
J Miss State Med Assoc; 2007 Jul; 48(7):206-7. PubMed ID: 17939254
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone-related acute leukemia in two MS patients.
Pielen A; Goffette S; Van Pesch V; Gille M; Sindic CJ
Acta Neurol Belg; 2008 Sep; 108(3):99-102. PubMed ID: 19115673
[TBL] [Abstract][Full Text] [Related]
18. Rationale for the use of mitoxantrone in multiple sclerosis.
Edan G; Morrissey S; Le Page E
J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
[TBL] [Abstract][Full Text] [Related]
19. Leukaemia due to mitoxantrone.
Prescrire Int; 2007 Aug; 16(90):153-6. PubMed ID: 17724842
[TBL] [Abstract][Full Text] [Related]
20. BLOOD COUNT IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH MITOXANTRONE IN SHORT TIME OBSERVATION.
Pastuszak Z; Stepien A; Tomczykiewicz K; Piusinska-Macoch R
Acta Pol Pharm; 2016 Sep; 73(5):1369-1373. PubMed ID: 29638077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
